Coronavirus-linked pregnancy complications: a comparative study

Gonlepa, Miapeh Kous; Rufai, Olayemi Hafeez; Ofuonye, Chidinmma Grace; Sebaka, Lapologang

doi:10.1186/s43042-022-00229-5

Cited by 4 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even though vertical transmission occurs rarely and can be symptomatic or asymptomatic, the risk of spreading the SARS-CoV-2 virus to the fetoplacental unit is considerable [ 59 , 60 ]. Pregnancy complications resulting from SARS-CoV-2 infection during pregnancy include miscarriage (2%), fetal growth restriction (10%), and premature labor (39%) [ 61 ].…”

Section: Resultsmentioning

confidence: 99%

miRNAs as a Potential Biomarker in the COVID-19 Infection and Complications Course, Severity, and Outcome

et al. 2023

View full text Add to dashboard Cite

During the last three years, since the emergence of the COVID-19 pandemic, a significant number of scientific publications have focused on resolving susceptibility to the infection, as well as the course of the disease and potential long-term complications. COVID-19 is widely considered as a multisystem disease and a variety of socioeconomic, medical, and genetic/epigenetic factors may contribute to the disease severity and outcome. Furthermore, the SARS-COV-2 infection may trigger pathological processes and accelerate underlying conditions to clinical entities. The development of specific and sensitive biomarkers that are easy to obtain will allow for patient stratification, prevention, prognosis, and more individualized treatments for COVID-19. miRNAs are proposed as promising biomarkers for different aspects of COVID-19 disease (susceptibility, severity, complication course, outcome, and therapeutic possibilities). This review summarizes the most relevant findings concerning miRNA involvement in COVID-19 pathology. Additionally, the role of miRNAs in wide range of complications due to accompanied and/or underlying health conditions is discussed. The importance of understanding the functional relationships between different conditions, such as pregnancy, obesity, or neurological diseases, with COVID-19 is also highlighted.

show abstract

Section: Resultsmentioning

confidence: 99%

miRNAs as a Potential Biomarker in the COVID-19 Infection and Complications Course, Severity, and Outcome

et al. 2023

View full text Add to dashboard Cite

show abstract

“…A contaminação pelo vírus em gestantes pode, ainda, cursar com fadiga, dor de garganta e de cabeça, mialgia (GRADOS IZ, et al, 2020), congestão nasal, rash cutâneo, expectoração, perda de apetite (AMORIM MMR, et al, 2021), podendo promover pneumonia materna grave, trabalho de parto prematuro, aborto espontâneo, restrição de crescimento fetal, ruptura prematura de membranas e até mesmo morte materna (AMORIM MMR, et al, 2021; RAJEWSKA A, et al, 2020; SCHWARTZ DA, 2020), havendo forte associação do óbito com comorbidades como doenças cardiovasculares, obesidade e diabetes (SOUZA ASR e AMORIM MMR, 2021) e tendo como principais causas a sepse grave e insuficiência respiratória progressiva (GONLEPA MK, et al, 2022). Foram relatados ainda desfechos que evoluíram com pré-eclâmpsia ou HELLP (síndrome caraterizada pela presença de hemólise, aumento de enzimas hepáticas e plaquetopenia (ADAM S, et al, 2022).…”

Section: Revisão Bibliógraficaunclassified

Manifestações associadas à infecção pela COVID-19 em mulheres gestantes: uma revisão narrativa

Morais¹,

Santos²,

Lopes³

et al. 2022

Acervo Saúde

View full text Add to dashboard Cite

Objetivo: Avaliar, por meio de uma revisão, as consequências da infecção pela COVID-19 em mulheres gestantes. Revisão bibliográfica: A infeção pelo coronavírus 19 (COVID-19) é uma patologia emergente que foi identificada pela primeira vez em dezembro de 2019, na China. A COVID-19 tem elevado potencial de morbidade, mortalidade e transmissão, atingindo pessoas de diversas idades e condições clínicas, incluindo as gestantes. As manifestações clínicas podem variar desde casos assintomáticos a casos mais graves, podendo chegar até à falência de órgãos e sepse. A maioria das gestantes apresenta apenas sintomas do tipo gripais ou febre, sendo este sintoma predominante, mas que nem sempre manifesta-se antes do nascimento do bebê. Geralmente o curso da doença é sem complicações, e a paciente tem alta hospitalar depois de alguns dias após a concepção. Entretanto, complicações sistêmicas e a necessidade de maior permanência no hospital foram associadas à gravidez. Considerações finais: As resultantes são muito variáveis, e vão desde sintomas simples como febre, dor de cabeça e tosse, até outros maiores e mais graves como pneumonia grave, a SDRA e até a morte.

show abstract

“…These efforts yielded several options with Emergency Use Authorization (EUA) status for treating COVID-19, of which some include dexamethasone 2 , RNA-dependent RNA polymerase inhibitors (molnupiravir and remdesivir), 3CLpro inhibitors (nirmatrelvir), monoclonal antibodies (MABs), and convalescent plasma 3 . However, most of these treatment options displayed major setbacks in large clinical trials in hospitalized patients, either exhibiting uncertain efficacy or serious side effects 4 , 5 . Moreover, the SARS-CoV-2 virus mutates frequently, and this is an obstacle to some potential drugs, and the emergence of viral escape mutants that render SARS-CoV-2 spike glycoprotein-targeting vaccines ineffective remains a possibility 6 , 7 .…”

Section: Introductionmentioning

confidence: 99%

MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference

Durojaye

Okoro

Odiba

et al. 2023

Sci Rep

View full text Add to dashboard Cite

SARS-CoV-2 infection has led to several million deaths worldwide and ravaged the economies of many countries. Hence, developing therapeutics against SARS-CoV-2 remains a core priority in the fight against COVID-19. Most of the drugs that have received emergency use authorization for treating SARS-CoV-2 infection exhibit a number of limitations, including side effects and questionable efficacy. This challenge is further compounded by reinfection after vaccination and the high likelihood of mutations, as well as the emergence of viral escape mutants that render SARS-CoV-2 spike glycoprotein-targeting vaccines ineffective. Employing de novo drug synthesis or repurposing to discover broad-spectrum antivirals that target highly conserved pathways within the viral machinery is a focus of current research. In a recent drug repurposing study, masitinib, a clinically safe drug against the human coronavirus OC43 (HCoV-OC43), was identified as an antiviral agent with effective inhibitory activity against the SARS-CoV-2 3CLpro. Masitinib is currently under clinical trial in combination with isoquercetin in hospitalized patients (NCT04622865). Nevertheless, masitinib has kinase-related side effects; hence, the development of masitinib analogs with lower anti–tyrosine kinase activity becomes necessary. In this study, in an attempt to address this limitation, we executed a comprehensive virtual workflow in silico to discover drug-like compounds matching selected pharmacophore features in the SARS-CoV-2 3CLpro-bound state of masitinib. We identified a novel lead compound, “masitinibL”, a drug-like analog of masitinib that demonstrated strong inhibitory properties against the SARS-CoV-2 3CLpro. In addition, masitinibL further displayed low selectivity for tyrosine kinases, which strongly suggests that masitinibL is a highly promising therapeutic that is preferable to masitinib.

show abstract

Coronavirus-linked pregnancy complications: a comparative study

Cited by 4 publications

References 9 publications

miRNAs as a Potential Biomarker in the COVID-19 Infection and Complications Course, Severity, and Outcome

miRNAs as a Potential Biomarker in the COVID-19 Infection and Complications Course, Severity, and Outcome

Manifestações associadas à infecção pela COVID-19 em mulheres gestantes: uma revisão narrativa

MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference

Contact Info

Product

Resources

About